Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer

Buhai Wang(Northern Jiangsu People's Hospital), Jingxu Gu(Roswell Park Comprehensive Cancer Center), Yinxia Wu(Yangzhou University), Yuxiang Huang(Heilongjiang Provincial Academy of Agricultural Sciences), Yichun Zeng(Northern Jiangsu People's Hospital), Xian Zhang(University of North Carolina at Chapel Hill), Yichen Liang, Wenmiao Cao(Northern Jiangsu People's Hospital), Liqin Liu(Xinjiang Agricultural University), Yuechao Wu(Changshu No.1 People's Hospital), Qiuxian Li(Leshan Normal University)
Journal for ImmunoTherapy of Cancer
November 1, 2024
10.1136/jitc-2024-009898
Cited by 12

Related Papers

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
|Gastroenterology|2020|692
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
Houttuynia-derived nitrogen-doped hierarchically porous carbon for high-performance supercapacitor
|Carbon|2020|432
Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta‐analysis
|Journal of Evidence-Based Medicine|2020|356
Time‐Resolved FRET Biosensor Based on Amine‐Functionalized Lanthanide‐Doped NaYF<sub>4</sub> Nanocrystals
|Angewandte Chemie International Edition|2011|328